A Venture Capitalist’s View of the Current Biotech Landscape episode artwork

EPISODE · Sep 6, 2023 · 43 MIN

A Venture Capitalist’s View of the Current Biotech Landscape

from The Bio Report · host Levine Media Group

Earlier this year, the venture capital firm SR One closed a $600 million fund, its second since spinning out from the pharmaceutical giant GSK. Despite the difficult investment landscape today for biotechs, it’s a reminder that significant capital is available to be deployed. We spoke to Simeon George, CEO and managing partner for SR One, about the firm’s investment approach, how the current landscape is causing venture capitalists and therapeutics developers to think differently, and what advice he’d offer entrepreneurs seeking to raise money today.  

Simeon George, CEO and managing partner for SR One, about the firm’s investment approach, how the current landscape is causing venture capitalists and therapeutics developers to think differently, and what advice he’d offer entrepreneurs seeking to raise money today.

NOW PLAYING

A Venture Capitalist’s View of the Current Biotech Landscape

0:00 43:52

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 43 minutes long.

When was this The Bio Report episode published?

This episode was published on September 6, 2023.

What is this episode about?

Earlier this year, the venture capital firm SR One closed a $600 million fund, its second since spinning out from the pharmaceutical giant GSK. Despite the difficult investment landscape today for biotechs, it’s a reminder that significant capital...

Can I download this The Bio Report episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!